ascopubs.org5d
Innovative diagnostic approaches: Serum protein markers in renal cell carcinoma.
Systemic therapies in renal cell carcinoma with brain metastases: A comparative meta-analysis of immunotherapy and tyrosine kinase inhibitors. PSMA-positive tumor vessels around renal cell carcinoma ...
ascopubs.org16h
Whole-slide multiplexed tissue imaging of prostate adenocarcinoma to investigate immune niches in high- versus low-grade tumors.
Developing a deep learning algorithm for automated p53 immunohistochemistry digital image analysis in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
ascopubs.org5d
Genomic characteristics of patients with metastatic hormone-sensitive prostate cancer treated with ARPI-based therapy: A single-center analysis.
Integrating aggressive variant prostate cancer–associated tumor suppressor genes (AVPC-TSG) status to refine prognosis and predict androgen-receptor pathway inhibitors (ARPI) response in metastatic ...
ascopubs.org27d
Pan-cancer microsatellite instability testing using a multiplex assay including long mononucleotide repeats.
The prevalence and prognostic significance of KRAS G12C mutation in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract ...
ascopubs.org5d
Genome-scale metabolic reconstruction of urinary microbiome: Pathway for personalized medicine.
TP53 Y220C mutations in advanced urothelial bladder cancer (UBC): A genomic landscape study. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...
ascopubs.org5d
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...
ascopubs.org6d
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update
Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...
ascopubs.org2d
Management of relapsed stage I seminomatous germ cell tumor with retroperitoneal or pelvic only relapse.
Clinical outcomes of stage IIA/IIB seminoma treated with radiotherapy and chemotherapy: Should regional therapy be considered the preferred treatment approach?
ascopubs.org5d
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...
ascopubs.org5d
Impact of prior primary care utilization on limiting racial disparities for prostate cancer diagnosis and mortality.
Ethnic disparities in clinical trials for FDA-approved drugs in prostate cancer: A post–COVID-19 era analysis (2020-2024). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers ...
ascopubs.org5d
Evaluation of de novo oligometastatic prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset.
Outcomes for 177Lu-PSMA-617 with and without concurrent use of ARPIs in patients with mCRPC.
ascopubs.org5d
A survival prediction model for veterans with advanced bladder cancer (BC) treated with immune checkpoint inhibitors (ICI).
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer. PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting ...